DOCSLIB.ORG

Application for Inclusion of Azithromycin for Yaws in the Who Model List of Essential Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application for Inclusion of Azithromycin for Yaws in the Who Model List of Essential Medicines WORLD HEALTH ORGANIZATION EDM/EC/ESD ORGANISATION MONDIALE DE LA SANTE ENGLISH ONLY EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL MEDICINES APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES FROM THE BARCELONA INSTITUTE FOR GLOBAL HEALTH (ISGLOBAL) APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL CONTENTS 1. Summary statement of the proposal for inclusion, change or deletion 4 2. Name of the focal point in WHO submitting the application 4 3. Name of the organization(s) consulted and/or supporting the application 4 4. International Nonproprietary Name (INN, generic name) of the medicine 4 5. Formulation(s) and strength(s) proposed for inclusion 4 6. Whether listing is requested as an individual medicine or as an example of a therapeutic group 6 7. Treatment details 7 7.1. General infections 7 7.2. Genital Chlamydia trachomatis and trachoma 7 7.3. Yaws 7 7.3.1. WHO Guideline 8 7.3.2. Diagnostic tests for yaws 8 7.3.3. Yaws for mass treatment 9 8. Information supporting the public health relevance 10 8.1. Yaws burden 10 8.2. Assessment of current use 10 8.3. Target populations 10 8.4. Likely impact of treatment on the disease 11 9. Summary of comparative effectiveness in a variety of clinical settings: 12 9.1. Identification of clinical evidence 12 9.2. Summary of available data 12 9.2.1. Studies on susceptibility of Treponema pallidum pertenue to azithromycin 12 9.2.2. Studies on efficacy of azithromycin to treat yaws 13 9.2.3. Studies on efficacy of mass azithromycin to treat yaws 14 9.3. Summary of available estimates of comparative effectiveness 15 10. Summary of comparative evidence on safety 17 10.1. Estimate of total patient exposure to date 17 10.2. Description of adverse effects/reactions 10.3 Summary of available data (appraisal of quality, summary of results) 18 10.3.1. Safety in mass drug administration programs 19 10.4. Summary of comparative safety against comparators 19 10.5. Identification of variation in safety due to health systems and patient factors 20 2 APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL CONTENTS (continued) 11. Summary of available data on comparative cost and cost-effectiveness within the pharmacological class or therapeutic group 22 11.1. Range of costs of the proposed medicine 22 11.1.1. Donation programme 22 11.2.Comparative cost-effectiveness presented as range of cost per routine outcome 23 12. Summary of regulatory status of the medicine 26 13. Availability of pharmacopoeial standards 27 14. References 28 3 APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL GENERAL ITEMS 1. SUMMARY STATEMENT OF THE PROPOSAL FOR INCLUSION, CHANGE OR DELETION Azithromycin is proposed for inclusion into the core WHO Model list of Essential Medicines for the treatment of yaws. Azithromycin is also proposed for inclusion on the WHO Model List of Essential Medicines for Children. 2. NAME OF THE WHO TECHNICAL DEPARTMENT AND FOCAL POINT SUPPORTING THE APPLICATION Submitted by ISGlobal via WHO/EDM. ISGlobal asked WHO/NTD for technical support. 3. NAME OF THE ORGANIZATION(S) CONSULTED AND/OR SUPPORTING THE APPLICATION Barcelona Institute for Global Health (ISGlobal) London School of Hygiene and Tropical Medicine (LSHTM) Department of Medicine and Global Health, University of Washington (UW) 4. INTERNATIONAL NONPROPRIETARY NAME (INN, GENERIC NAME) OF THE MEDICINE Azithromycin (rINN, BAN, USAN) 5. FORMULATION(S) AND STRENGTH(S) PROPOSED FOR INCLUSION; INCLUDING ADULT AND PAEDIATRIC Capsule: 250 mg; 500 mg (anhydrous). Oral liquid: 200 mg/5 mL. Market availability: International Brand Names: Ajustin (KR); Aratro (ES); Atizor (CL); ATM-200 (TZ); Aza-250 (HK); Aza-500 (HK); Azadose (FR); Azas (KR); Azath (KR); Azatril (EE); Azax (TR); Azbact (LK); Azee (HK); Azeemycin (PH); Azenil (IL); Azi-500 (PH); Azibact (DE, IN); Azibiot (LV, RO); Azicine (HK, VN); Azilide-250 (PH); Azilide-500 (PH); Azimac (SA); Azimax (MY); Azimax-250 (HK, SG); Azimed (HR); Azin (BD, PH); Azinobin (CO); Aziphar (VN); Azirocin (KR); Azith (AU, TH); Azithral (IN); Azithrin (MT); Azithro (MY); Azithrom (TW); Azitops (KR); Azitrex (EC); Azitrix (PT); Azitrocin (IT, PH); Azitromax (NO, SE); Azitrox (SK); Aziwin (ID); Aziwok (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW); Azomax (BH, KW); Azomycin (AE, KW, QA, SA); Azomyne (JO, LB, QA); Azox (JO); Azro (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Aztrin (ID); Azyth (PH); Azytsyn (UA); Binozyt (HK, ID, KR, LK, SG, TH, VN); Clindal AZ (BR, HK); Cronopen (AR); Decantin (PH); Ethrimax DS (ID); Floctil (HK, MY, TH); Geozif (VN); Geozit (PH); Glazi (VN); Imexa (HK, MY); Inedol (PE); Jazit (PH); Koptin (CR, DO, GT, HN, NI, PA, SV); Kromicin (CO); Macromax (PH); Macrozit (CO, PE); Maxmor (ID); Meithromax (TH); Mezatrin (ID); Neazi (VN); OD Mac (PH); Odazyth (BD); Onzet (TH); Ormaks (UA); Shepherd (CN); Sumamed (BG, CN, CZ, EE, LV, PL, SK); Thromaxin (PH); 4 APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL Tromix (CO); Ultreon (DE); Uzet (LK); Vinzam (BD); Weihong (CN); Wiltrozin (PH); Xithrone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Zaha-250 (TZ); Zaret (CO); Zarom (ID); Zedbac (GB); Zedd (AU); Zenith (PH); Zeto (IL); Zetron (LB); Zicho (ID); Zimac (SA); Zimax (LB); Zimericina (CO); Zinfect (TR); Zistic (ID); Zitaspen (ZW); Zithrax (ID); Zithromac SR (JP); Zithromax (AE, AT, AU, BD, BF, BH, BJ, CH, CI, CL, CN, CY, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, ID, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NZ, OM, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG,US, YE, ZA, ZM, ZW); Zithromax IV (MY, SG, US); Zithrox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LK, LY, OM, QA, SA, SY, YE); Zitrim (CO); Zitrocin (PY); Zitromax (AR, BE, BR, CR, DK, EC, ES, GT, HN, IS, IT, LU, NI, PA, PE, SV, TR, UY, VE); Zmax (IL, SG, ZW); Zmax One Dose (PH); Zocin (AE, JO); Zomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Zymed (ID); Zynomax (MY); Zythrocin (TW); Zytroks (UA) FDA approved manufacturers: Azithromycin for suspension; oral Manufacturer: PFIZER Approval date: September 28, 1994 Strength(s): EQ 1GM BASE/PACKET [RLD] Manufacturer: PFIZER Approval date: October 19, 1995 Strength(s): EQ 100MG BASE/5ML [AB], EQ 200MG BASE/5ML [RLD] [AB] Manufacturer: PLIVA Approval date: July 5, 2006 Strength(s): EQ 100MG BASE/5ML [AB], EQ 200MG BASE/5ML [AB] Manufacturer: TEVA PHARMS Approval date: June 24, 2008 Strength(s): EQ 100MG BASE/5ML [AB], EQ 200MG BASE/5ML [AB] Azithromycin tablet; oral Manufacturer: PFIZER Approval date: June 12, 1996 Strength(s): EQ 600MG BASE [RLD] [AB] Manufacturer: PFIZER Approval date: July 18, 1996 Strength(s): EQ 250MG BASE [AB] Manufacturer: PFIZER Approval date: May 24, 2002 Strength(s): EQ 500MG BASE [AB] 5 APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL Manufacturer: APOTEX CORP Approval date: July 13, 2011 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Manufacturer: LUPIN LTD Approval date: May 15, 2015 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Manufacturer: MYLAN Approval date: January 8, 2007 Strength(s): EQ 600MG BASE [AB] Manufacturer: MYLAN Approval date: May 30, 2007 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB] Manufacturer: PLIVA Approval date: November 14, 2005 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Manufacturer: SANDOZ Approval date: November 14, 2005 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Manufacturer: TEVA Approval date: November 14, 2005 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Manufacturer: WOCKHARDT Approval date: February 11, 2008 Strength(s): EQ 250MG BASE [AB], EQ 500MG BASE [AB], EQ 600MG BASE [AB] Source: Drugs.com 6. WHETHER LISTING IS REQUESTED AS AN INDIVIDUAL MEDICINE OR AS AN EXAMPLE OF A THERAPEUTIC GROUP Azithromycin is the prototype of a subclass of macrolide antibiotics known as the azalides. Listing is requested as an individual medicine. If other equivalent molecules are developed, azithromycin can become an example of the therapeutic group. 6 APPLICATION FOR INCLUSION OF AZITHROMYCIN FOR YAWS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES ISGLOBAL 7. TREATMENT DETAILS 7.1. General infections Azithromycin is effective in treating acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae; pharyngitis/tonsillitis due to S. pyogenes, community-acquired pneumonia due to Chlamydia (also known as Chlamydophila) pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae; acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to H. influenzae, M. catarrhalis, or S. pneumoniae; acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae; prevention of Mycobacterium avium complex (MAC) (alone or in combination with rifabutin) in patients with advanced HIV infection; treatment of disseminated MAC (in combination with ethambutol) in patients with advanced HIV infection; skin and skin structure infections (uncomplicated) due to S. aureus, S. pyogenes, or S. agalactiae; sexually transmitted infections (urethritis, cervicitis and chancroid and genital ulcer disease in men) due to C.
Load more

Recommended publications
  • FDA-Approved Drugs with Potent in Vitro Antiviral Activity Against Severe Acute Respiratory Syndrome Coronavirus 2
    pharmaceuticals Article FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2 1, , 1, 2 1 Ahmed Mostafa * y , Ahmed Kandeil y , Yaseen A. M. M. Elshaier , Omnia Kutkat , Yassmin Moatasim 1, Adel A. Rashad 3 , Mahmoud Shehata 1 , Mokhtar R. Gomaa 1, Noura Mahrous 1, Sara H. Mahmoud 1, Mohamed GabAllah 1, Hisham Abbas 4 , Ahmed El Taweel 1, Ahmed E. Kayed 1, Mina Nabil Kamel 1, Mohamed El Sayes 1, Dina B. Mahmoud 5 , Rabeh El-Shesheny 1 , Ghazi Kayali 6,7,* and Mohamed A. Ali 1,* 1 Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; [email protected] (A.K.); [email protected] (O.K.); [email protected] (Y.M.); [email protected] (M.S.); [email protected] (M.R.G.); [email protected] (N.M.); [email protected] (S.H.M.); [email protected] (M.G.); [email protected] (A.E.T.); [email protected] (A.E.K.); [email protected] (M.N.K.); [email protected] (M.E.S.); [email protected] (R.E.-S.) 2 Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt; [email protected] 3 Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, USA; [email protected] 4 Department of Microbiology and Immunology, Zagazig University, Zagazig 44519, Egypt; [email protected] 5 Pharmaceutics Department, National Organization for Drug Control and Research, Giza 12654, Egypt; [email protected] 6 Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA 7 Human Link, Baabda 1109, Lebanon * Correspondence: [email protected] (A.M.); [email protected] (G.K.); [email protected] (M.A.A.) Contributed equally to this work.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Options
    Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment.
    [Show full text]
  • Azithromycin (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Azithromycin (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Zithromax; Zithromax Tri-Pak; Zithromax Z-Pak; Zmax [DSC] Brand Names: Canada ACT Azithromycin [DSC]; AG-Azithromycin; APO-Azithromycin; APO-Azithromycin Z; AURO-Azithromycin; DOM-Azithromycin; GD-Azithromycin [DSC]; GEN- Azithromycin; JAMP-Azithromycin; M-Azithromycin; Mar-Azithromycin; MYLAN- Azithromycin [DSC]; NRA-Azithromycin; PHL-Azithromycin [DSC]; PMS- Azithromycin; PRO-Azithromycin; RATIO-Azithromycin; RIVA-Azithromycin; SANDOZ Azithromycin; TEVA-Azithromycin; Zithromax What is this drug used for? It is used to treat or prevent bacterial infections. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have turned yellow or had liver side effects with this drug before. If you have any of these health problems: Long QTc on ECG or other heartbeat that is not normal, slow heartbeat, or low potassium or magnesium levels. If you have heart failure (weak heart). Azithromycin (Systemic) 1/8 If you have ever had a certain type of abnormal heartbeat (torsades de pointes). If you are taking any drugs that can cause a certain type of heartbeat that is not normal (prolonged QT interval). There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure.
    [Show full text]
  • A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
    DOI: 10.14744/ejmo.2021.16263 EJMO 2021;5(1):63–70 Research Article A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients Abu Taiub Mohammed Mohiuddin Chowdhury,1 Mohammad Shahbaz,2 Md Rezaul Karim,3 Jahirul Islam, Guo Dan,1 Shuixiang He1 1Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 2Chakoria Upazilla Health Complex, Cox’s Bazar, Bangladesh 3Biomedical Research Institute of Hubei University of Medicine, Shiyan, China 4Department of Epidemiology and Health Statistics, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China Abstract Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combina- tion therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithro- mycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symp- tomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days.
    [Show full text]
  • Guidance for Treatment of Covid-19 in Adults and Children
    GUIDANCE FOR TREATMENT OF COVID-19 IN ADULTS AND CHILDREN Patient population: Adults and pediatric patients with COVID-19 infection, who are admitted on an inpatient floor or to the intensive care unit. Key points: Details regarding isolation/precautions, personal protective equipment, patient movement, family/visitor policy, and cleaning/disinfection can be found here. Clinical symptoms: Range from asymptomatic, uncomplicated upper respiratory tract viral infection to pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock (Table 1) Diagnosis: See current COVID-19 testing recommendations. Treatment: Based on data from several randomized control trials, Remdesivir may provide a modest benefit in a subgroup of patients hospitalized with COVID-19. See further details regarding patient populations (see below) and Table 2. Table 1. Potential Treatment Recommendations by Severity of Disease for Patients 18 Years or Older Most COVID-19 therapeutics have not been studied in children under 18. The below treatment recommendations may apply to some children, however should be addressed on a case-by-case basis and discussed with Pediatric Infectious Diseases. See specific sections for further details Disease severity Potential Treatment Recommendations (per ID consult discretion based on details in Table 2) Post-exposure prophylaxis • See Post-Exposure Prophylaxis Guidelines No supplemental oxygen • Supportive care • Monoclonal Antibodies may be an option in certain high-risk patients (see eligibility criteria in Table 2) admitted for reasons other than COVID-19 who have mild to moderate symptoms of COVID-19 Low flow supplemental oxygen • Supportive care • Dexamethasone (Exception: Minimal supplemental oxygen (1-2 L) in adults with <7 days of symptoms—uncertain benefit) • Remdesivir High flow supplemental oxygen or non- • Supportive Care invasive mechanical ventilation • Dexamethasone • Tocilizumab (NOTE: currently on shortage and not available for treatment of COVID-19 in patients 18 years an older.
    [Show full text]
  • Guidelines for the Management of Sexually Transmitted Infections
    GUIDELINES FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS 3. TREATMENT OF SPECIFIC INFECTIONS 3.1. GONOCOCCAL INFECTIONS A large proportion of gonococcal isolates worldwide are now resistant to penicillins, tetracyclines, and other older antimicrobial agents, which can therefore no longer be 32 recommended for the treatment of gonorrhoea. TREATMENT OF SPECIFIC INFECTIONS SPECIFIC OF TREATMENT It is important to monitor local in vitro susceptibility,as well as the clinical efficacy of recommended regimens. Note In general it is recommended that concurrent anti-chlamydia therapy be given to all patients with gonorrhoea, as described in the section on chlamydia infections, since dual infection is common.This does not apply to patients in whom a specific diagnosis of C. trachomatis has been excluded by a laboratory test. UNCOMPLICATED ANOGENITAL INFECTION Recommended regimens I ciprofloxacin, 500 mg orally,as a single dose OR I azithromycin, 2 g orally,as a single dose OR I ceftriaxone, 125 mg by intramuscular injection, as a single dose OR I cefixime, 400 mg orally,as a single dose OR I spectinomycin, 2 g by intramuscular injection, as a single dose. Note I Ciprofloxacin is contraindicated in pregnancy.The manufacturer does not recommend it for use in children and adolescents. GUIDELINES FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS I There is accumulating evidence that the cure rate of Azithromycin for gonococcal infections is best achieved by a 2-gram single dose regime.The 1-gram dose provides protracted sub-therapeutic levels which may precipitate the emergence of resistance. There are variations in the anti-gonococcal activity of individual quinolones, and it is important to use only the most active.
    [Show full text]
  • Impetigo: Antimicrobial Prescribing
    DRAFT FOR CONSULTATION 1 Impetigo: antimicrobial prescribing 2 NICE guideline 3 Draft for consultation, August 2019 This guideline sets out an antimicrobial prescribing strategy for impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations in this guideline are for the use of antiseptics and antibiotics to manage impetigo in adults, young people and children. It does not cover diagnosis. Please note that the scope of this guideline is for adults, young people and children aged 72 hours and over. For treatment of children in the first 72 hours of life, please seek specialist advice. For managing other skin infections, see our web page on skin conditions. See a 2-page visual summary of the recommendations, including tables to support prescribing decisions. Who is it for? • Healthcare professionals • Adults, young people and children with impetigo, their parents and carers The guideline contains: • the draft recommendations • the rationales • summary of the evidence. Information about how the guideline was developed is on the guideline’s page on the NICE website. This includes the full evidence review, details of the committee and any declarations of interest. Impetigo: antimicrobial prescribing guidance DRAFT (August 2019) Page 1 of 20 DRAFT FOR CONSULTATION 1 Recommendations 2 1.1 Managing impetigo 3 Advice to reduce the spread of impetigo 4 1.1.1 Advise adults, young people and children, and their parents or 5 carers if appropriate, about good hygiene measures to reduce the 6 spread of impetigo to other areas of the body and to other people. To find out why the committee made the recommendations on advice to reduce the spread of impetigo see the rationales.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Antibiotic Prophylaxis 2017 Update
    Distribution Information AAE members may reprint this position statement for distribution to patients or referring dentists. Antibiotic Prophylaxis 2017 Update AAE Quick Reference Guide About This Document This paper is designed to Endocarditis Prophylaxis Recommendations provide scientifically based These recommendations are taken from 2017 American Heart Association and guidance to clinicians American College of Cardiology focused update of the 2014 AHA/ADA Guideline regarding the use of antibiotics for Management of Patients with Valvular Disease (1) and cited by the ADA (2). in endodontic treatment. Thank you to the Special Committee on Antibiotic Use in Prophylaxis against infective endocarditis is reasonable before dental Endodontics: Ashraf F. Fouad, procedures that involve manipulation of gingival tissue, manipulation of the Chair, B. Ellen Byrne, Anibal R. periapical region of teeth, or perforation of the oral mucosa in patients with the Diogenes, Christine M. Sedgley following: and Bruce Y. Cha. In 2017, the AHA and American College of Cardiology (ACC) published ©2017 a focused update (5) to their previous guidelines on the management of valvular heart disease. This reinforced their previous recommendations that AP is reasonable for the subset of patients at increased risk of developing IE and at high risk of experiencing adverse outcomes from IE (5). Their key recommendations were: 1. Prosthetic cardiac valves, including transcatheter-implanted prostheses and homografts. 2. Prosthetic material used for cardiac valve repair, such as annuloplasty rings and chords. 3. Previous IE. 4. Unrepaired cyanotic congenital heart disease or repaired congenital heart disease, with residual shunts or valvular regurgitation at the site of or adjacent to the site of a prosthetic patch or prosthetic device.
    [Show full text]
  • Comparing Two Types of Macrolide Antibiotics for the Purpose of Assessing Population-Based Drug Interactions
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2013-002857 on 11 July 2013. Downloaded from Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions Jamie L Fleet,1 Salimah Z Shariff,1,2 David G Bailey,3 Sonja Gandhi,1,4 David N Juurlink,2,5,6 Danielle M Nash,1,2 Muhammad Mamdani,2,6,7 Tara Gomes,2 Amit M Patel,1 Amit X Garg1,2,4 To cite: Fleet JL, Shariff SZ, ABSTRACT et al ARTICLE SUMMARY Bailey DG, . Comparing Objective: Clarithromycin strongly inhibits enzyme two types of macrolide cytochrome P450 3A4, preventing the metabolism of antibiotics for the purpose of Article focus some other drugs, while azithromycin is a weak assessing population-based ▪ This study describes the differences in adverse drug interactions. BMJ Open inhibitor. Accordingly, blood concentrations of other outcomes when either clarithromycin or azithro- 2013;3:e002857. drugs increase with clarithromycin coprescription mycin is prescribed in the absence of interacting doi:10.1136/bmjopen-2013- leading to adverse events. These macrolide antibiotics drugs. 002857 also differ on other properties that may impact ▪ Knowledge of the underlying differences between outcomes. In this study, we compared outcomes in these two drugs is important for the interpret- ▸ Prepublication history and two groups of macrolide antibiotic users in the ation of population-based drug–drug interaction additional material for this absence of potentially interacting drugs. studies. paper is available online. To Design: Population-based retrospective cohort study. view these files please visit Setting: Ontario, Canada, from 2003 to 2010.
    [Show full text]
  • Would There Be Pharmacodynamics Without Pharmacokinetics?
    AGORA | CORRESPONDENCE Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? To the Editor: We read with great interest the recent publication by KWAK et al. [1] involving a meta-analysis of studies reporting treatment outcomes for Mycobacterium abscessus pulmonary disease (MAB-PD). The authors should be commended for identifying the association between azithromycin, amikacin and imipenem, and improved clinical outcome in MAB-PD. M. abscessus, together with M. avium complex (MAC) and M. kansasii, is one of the most common and difficult to treat nontuberculous mycobacteria (NTM) species associated with pulmonary disease [2]. Treatment regimen for NTM infections is largely empirical and driven by clinical experience. Without sound pharmacokinetic (PK)- and pharmacodynamic (PD)-based guidelines on dose, frequency, dose adjustment or monitoring, clinicians are left with uncertainties when it comes to the specifics of prescribing a drug regimen. There is a great need for evidence-based dosing and monitoring strategies. We would like to kindly alert the authors, other clinicians and researchers about the importance of pharmacokinetics and pharmacodynamics when considering therapeutic effects of drugs. Unfortunately, the authors did not consider collecting PK data, drug exposure (e.g. peak concentration (Cmax)orarea under the concentration time curve AUC)) or therapeutic drug monitoring (TDM) interventions from the original studies. Although CONNELL and WILKIE [3] emphasised the importance of future high-quality studies in their editorial, PK/PD was not addressed. Interestingly, when we looked through the eight original studies included in their final analysis, two studies included PK data. One of them was the study −1 by NAMKOONG et al.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]